Identification of resistance mechanisms to EGFR treatment in the real world using a clinicogenomic database Published April 2018 Citation Singal, G, Li, G, Agarwala, V, Kaushik, G, O’Connell, C, Alpha-CobbG, Caron, T, Bourque, D, Guria, A, Frank, S, Frampton, G, Carson, K, Abernethy, A.P., Miller, V.A. . AACR Annual Meeting. . https://4076230.fs1.hubspotusercontent-na1.net/hubfs/4076230/flatiron-com-pdf/AACR-2018-FH-FMI-CGDB-Poster-180411.pdf Authors: Sources:American Association for Cancer Research Annual Meeting Share Posted inPublicationsDrug discovery More publicationsBlood Cancer JournalDecember 2025Utilization of real-world evidence in regulatory approvals for multiple myeloma therapiesTaylor L, Chen A, Pierre A. Publication summaryPublicationsMultiple myelomaRegulatorySABCSDecember 2025Real-world glucagon-like peptide-1 use and association with clinical characteristics, social determinants, and circulating tumor DNA positivity in patients with breast cancerRyals C, Blarre A, Adamson B, et al.Publication summaryPublicationsBreast cancerSABCSDecember 2025Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024Meisel J, Pham T, Chen C, Kris A, Roose JPublication summaryPublications